Recombinant modified vaccinia virus Ankara-based malaria vaccines. (2nd January 2016)

• Record Type: Journal Article
• Authors: Sebastian, Sarah; Gilbert, Sarah C.
• Is Part Of: Expert review of vaccines. Volume 15:Number 1(2016)
• Page Start: 91
• Page End: 103
• Publication Date: 2016-01-02
• Subjects: modified vaccinia virus Ankara (MVA) -- malaria -- plasmodium -- vaccine -- clinical trials -- heterologous prime-boost; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/14760584.2016.1106319
• Languages: English
• ISSNs: 1476-0584

Abstract

Abstract : A safe and effective malaria vaccine is a crucial part of the roadmap to malaria elimination/eradication by the year 2050. Viral-vectored vaccines based on adenoviruses and modified vaccinia virus Ankara (MVA) expressing malaria immunogens are currently being used in heterologous prime-boost regimes in clinical trials for induction of strong antigen-specific T-cell responses and high-titer antibodies. Recombinant MVA is a safe and well-tolerated attenuated vector that has consistently shown significant boosting potential. Advances have been made in large-scale MVA manufacture as high-yield producer cell lines and high-throughput purification processes have recently been developed. This review describes the use of MVA as malaria vaccine vector in both preclinical and clinical studies in the past 5 years.